Mitosis is one of the most fundamental processes of life by which a mammalian cell divides into two daughter cells. Mitosis has been an attractive target for anticancer therapies since fast proliferation was identified as one of the hallmarks of cancer cells. Despite efforts into developing specific inhibitors for mitotic kinases and kinesins, very few drugs have shown the efficiency of microtubule targeting-agents in cancer cells with paclitaxel being the most successful. A deeper translational research accompanying clinical trials of anti-mitotic drugs will help in identifying potent biomarkers predictive for response. Here, we review the current knowledge of mitosis targeting agents that have been tested so far in the clinics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-3-319-57127-0_6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting chromosomally unstable tumors with a selective KIF18A inhibitor.
Nat Commun
January 2025
Volastra Therapeutics, New York, NY, USA.
Chromosome instability is a prevalent vulnerability of cancer cells that has yet to be fully exploited therapeutically. To identify genes uniquely essential to chromosomally unstable cells, we mined the Cancer Dependency Map for genes essential in tumor cells with high levels of copy number aberrations. We identify and validate KIF18A, a mitotic kinesin, as a vulnerability of chromosomally unstable cancer cells.
View Article and Find Full Text PDFSynthesis and modification of noscapine derivatives as promising future anticancer agents.
Bioorg Chem
December 2024
Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Evin, 1983963113 Tehran, Iran. Electronic address:
Noscapine, a tetrahydroisoquinoline alkaloid, was first isolated from Papaver somniferum and identified by Rabiquet in 1817. It has been used as an anti-tussive agent since the mid-1950 s. After the discovery of its anti-mitotic potential, it was into the limelight once again.
View Article and Find Full Text PDFAn anti-mitotic compound, (+)-6-tuliposide A, isolated from the Canadian glacier lily, Erythronium grandiflorum.
Fitoterapia
September 2024
Natural Product Laboratory, University of Lethbridge, 4401 University Drive W, Lethbridge, AB T1K 3M4, Canada. Electronic address:
The Canadian prairie ecosystem is subjected to abiotic and biotic conditions that induce plants to produce secondary metabolites that affect mammalian physiology. Extracts prepared from certain plant species native to Canadian prairie and montane cordillera ecosystems have previously been shown to have anti-mitotic activity on human cancer cell lines. In this study, we investigated the glacier lily, Erythronium grandiflorum (Liliaceae), in which the species was the most phylogenetically distant from Asteraceae and had anti-mitotic activity.
View Article and Find Full Text PDFOrnidazole Inhibits the Angiogenesis and Migration Abilities of Non-small Cell Lung Cancer (NSCLC) via Downregulation of VEGFA/VEGFR2/NRP-1 and PI3K/AKT/mTOR Pathways.
Cell Biochem Biophys
December 2024
Department Of Medical Services And Techniques, Kahramanmaraş Health Services Vocational School, Pathology Laboratory Techniques Pr., Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.
Article Synopsis
- Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide, and current treatments are inadequate, highlighting the need for new therapies.
- Ornidazole, a drug primarily used for treating parasitic infections, was studied for its effects on NSCLC cells, showing promise in reducing cell viability, migration, and angiogenesis.
- The findings suggest Ornidazole could be an effective new treatment option for NSCLC by targeting the molecular pathways involved in tumor growth and spread.
Discovery of novel octahydroquinazoline scaffolds endowed with dual inhibition of tubulin polymerization/Eg5 against HCC: Apoptotic and radio-chemotherapeutic studies.
Bioorg Chem
July 2024
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sinai University, Arish branch, Arish 45511, Egypt.
Mitotic kinesin Eg5 isozyme as a motor protein plays a critical role in cell division of tumor cells. Kinesin Eg5 selective inhibitors and Colchicine binding site suppressors are essential targets for many anticancer drugs and radio chemotherapies. On this work, a new series of octahydroquinazoline as anti-mitotic candidates 2-13 has been synthesized with dual inhibition of tubulin polymerization/Eg5 against HCC cell line.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!